Innovative research to facilitate women’s health

Invent Medic develops and offers research-based products that contribute to more freedom, joy and an active lifestyle.

 

In the fall of 2021, we are conducting a share issue to invest in focused marketing and sales activities.

 

Read about EfemiaRead about the capital raise on our share issue page (in Swedish)

Interim report Q2 2021 (in Swedish)

”Successful marketing focus on training incontinence”

Press release September 9, 2021 (in Swedish)

“Invent Medic conducts rights issue to finance focused marketing and sales activities”

Article published August 27, 2021 (in Swedish)

“Increased focus on marketing and upcoming launch”

Today, Efemia is available in several European markets including the UK and Germany, with over 8 million potential users in total. We are now working to include additional European markets and to prepare for a potential future launch in the United States, while also developing/evaluating additional products.

Karin Bryder

CEO, Invent Medic Sweden

Q2 2021

Forecast: Potential Efemia users

  • 2018 – 0.5 million (swe)
  • 2019 – 8 million (+dan, ger, uk, nor)
  • 2020 – 15 million (+ned, bel and more eu countries)
  • 2021 – 35 million (+the us and additional countries)

The forecast is based on Invent Medic’s expansion plans and an estimation of women with bothersome SUI in each market. In studies, around 70% of the participants have stated that they see themselves continue to use Efemia.